Page 5 - Sarcoma Unit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sarcoma unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sarcoma Unit Today - Breaking & Trending Today

FDA Grants Orphan Drug Designation to Tigilanol Tiglate in Soft Tissue Sarcoma

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma. ....

Intratumoral Tigilanol Tiglate , Qbiotics Group , Strategic Alliances , Investor Relations , Drug Designation , Orphan Drug Designation , Clinical Study , Soft Tissue , Fda Orphan Drug Designation , Tigilanol Tiglate , Soft Tissue Sarcoma ,

Presurgical Immunotherapy May Improve Survival in Certain Sarcomas

Treatment with immunotherapy demonstrated positive results regarding survival in patients with two types of soft-tissue sarcomas, research found. ....

United States , Christina Roland , Neeta Somaiah , University Of Texas Md Anderson Cancer Center , Md Anderson Cancer Center , National Cancer Institute , Nature Cancer , Clinical Trials , Cancer Center ,

Chest CT Imaging Patterns Contradict ACR Guidelines for Extremity Sarcoma Staging and Surveillance

R. Lor Randall, MD, FACS, explains the next steps in ensuring adherence to clinical care guidelines in extremity sarcoma. ....

United States , University Of California Davis , University Of California Uc Davis , Connective Tissue Oncology Society , Department Of Orthopedic Surgery , Musculoskeletal Tumor Society , American College Of Radiology , Cancer Center , Uc Davis Comprehensive Cancer Center , American College , David Linn Endowed Chair , Orthopedic Surgery , Comprehensive Cancer Center , Chest Ct Imaging , Acr Guidelines , American College Of Radiology , R Lor Randall , Guideline Committees ,

FDA Accepts Priority Review for Novel Synovial Sarcoma Drug

Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review. ....

Adrian Rawcliffe , Dennis Williams , Drug Administration , National Cancer Institute , Biologics License Application , Adaptimmune Therapeutics , Clinical Oncology ,

Bringing Lessons from Cancer to the Next Chapter

Cancer has taught me valuable lessons and now, I'm letting these lessons guide me. ....

New York , United States ,